Abstract: Blockade of CD44v7 was described to cure trinitrobenzene sulfonic acid-induced colitis, a disease not developed by mice with targeted deletion of the CD44v7 exon. There was evidence for a reduction in activation-induced cell death on lamina propria lymphocytes of control as compared with CD44v7-deficient mice. To elucidate the mechanism underlying the relative apoptosis resistance of CD44v7-competent as compared with CD44v7-deficient lymphocytes, T cell activation and induction of apoptosis were analyzed on mesenteric lymph node cells and Peyer's patch lymphocytes of CD44v7-deficient and CD44v4-v7-transgenic mice, which overexpress rat CD44v4-v7 on T lymphocytes. CD44v7 deficiency was characterized by an increase in the percentage of apoptotic cells after stimulation, increased numbers of CD95L-and CD152-positive cells, low levels of the anti-apoptotic proteins Bcl-2 and Bcl-Xl, and decreased phosphorylation of the pro-apoptotic protein BAD. Also, lymphocytes from CD44v4-v7-transgenic mice displayed reduced levels of CD95L, low numbers of apoptotic cells, and constitutively elevated levels of Bcl-Xl. When stimulating lymphocytes by CD3 cross-linking, CD44v7 was not recruited toward the immunological synapse and preferentially associated with the cytoskeletal-linker protein ezrin. Thus, as opposed to the CD44 standard isoform, CD44v7 does not function as an accessory molecule; instead, it supports survival of activated T cells by interfering with activation-induced cell death. J. Leukoc. Biol. 74: 135-148; 2003.
INTRODUCTION
Chronic inflammatory bowel disease (IBD), such as Morbus Crohn and colitis ulcerosa, are frequent and can become life threatening [1] . Serious efforts are being undertaken to develop new therapeutic modalities besides salicylates, corticosteroids, and cytostatica, which are effective but burdened by serious side-effects [2] . More recent therapeutic modalities are concentrating on selective interference with parameters associated with T cell activation, such as blockade of adhesion molecules, costimulatory molecules, and proinflammatory cytokines or administration of anti-inflammatory cytokines [3] [4] [5] [6] [7] . These trials are based on studies in experimental models, such as interleukin (IL)-10-, IL-2-, or T cell receptor (TCR)␣-knockout mice [8 -11] , which spontaneously develop colitis on druginduced models, such as trinitrobenzene sulfonic acid (TNBS) and dextran sodium sulfate, and on the transfer of a selected T cell population into severe combined immunodeficiency mice to induce colitis [12, 13] .
These models provided convincing evidence for T helper cell type 1 (TH-1) cytokines as an essential component in IBD [3, 14, 15] . Yet, apparently IL-12 plays a pivotal role only during the early period of IBD [16] . It also has been shown that IL-2 Ϫ/Ϫ mice with a targeted deletion of CD28 still develop colitis [17] . Both findings suggest that additional regulatory mechanisms are involved in the persisting activation of T cells in IBD. It is known that IBD is associated with high levels of CD40 and CD40L expression [18] , but mainly, it has been suggested that regulatory elements may be altered [19] . Besides a suggested control of DC activation via CD4 ϩ CD25 ϩ regulatory T cells [20] , it was described that CD4 ϩ CD25 ϩ T cells signal via cytotoxic T-lymphocyte antigen (CTLA)-4 and that constitutive expression of CTLA-4 is mainly restricted to these regulatory T cells [21] . It has also been noted that lamina propria lymphocytes (LPL) from inflamed tissue do not respond to down-regulatory signals such as IL-4 [22] . Recently, it also has been reported that LPL of patients with IBD display a marked reduction in apoptosis [23] , and also that despite normal levels of CD95 expression, T cells are more resistant to CD95-induced apoptosis, which may be a result of elevated levels of Bcl-2 [24] .
We described that CD44v7 appears to be directly involved in the chronification of gut-associated inflammatory processes, as an inflammation but no persisting colitis could be induced in CD44v7
Ϫ/Ϫ mice. Initial experimental evidence pointed toward elevated levels of activation-induced cell death (AICD) in CD44v7
Ϫ/Ϫ mice [25] . Furthermore, whereas mice with a targeted deletion of IL-10 spontaneously develop colitis, mice with a targeted deletion of IL-10 and CD44v7 do not develop colitis [25] . Finally, the development of a chronic colitis could be prevented by the application of a CD44v7-specific monoclonal antibody (mAb) [26] .
Despite the involvement of CD44v7 in IBD and delayed-type hypersensitivity reactions, not much is known about its mode of action [25] [26] [27] . CD44 comprises a set of transmembrane glycoproteins, whose members differ by glycosylation [28] and by insertion of up to 10 variant exons between exon 5 and exon 6 of the CD44 standard isoform (CD44s) [29] , which is expressed rather ubiquitously. The multitude of so-called variant isoforms (CD44v) is expressed in a tissue-related and developmentally restricted manner [30] . Considering functions of CD44 on hematopoietic cells, CD44s has been described as a lymphocyte homing receptor [30, 31] . In addition, the molecule is involved in lymphocyte maturation [32, 33] , traffic [34, 35] , and activation [36 -38] . CD44s functions as a costimulatory molecule in T cell activation as a result of its constitutive association with lck and its apposition toward the TCR upon stimulation and formation of the immunological synapse [39] . It is well known that formation of the immunological synapse is accompanied by redistribution of the actin cytoskeleton [40 -42] , and cross-linking CD44, too, leads to actin bundle formation in a RAC-dependent manner [43] .
Already in 1991, Haynes et al. [44] suggested that the multitude of CD44 isoforms mediates a multitude of functions, a prediction that experimentally has been well supported. Nevertheless, with the exception of the proteoglycan isoforms CD44v3 and CD44v10 [45, 46] , knowledge of ligands and/or signal transduction initiated selectively via CD44v isoforms is still scarce. It has been suggested that CD44 associates with the cytoskeletal linker proteins ankyrin and the ezrin, radixin, moesin (ERM) family including merlin [47] [48] [49] [50] [51] [52] and that the association with the ERM family may depend on the expression of CD44v isoforms [48] . It should also be mentioned that anchoring lipid rafts to the cytoskeleton through Cbp-EBP50-ERM has a negative effect on immune-synapse formation [53, 54] and that the association with ERM is responsible for the exclusion of CD43 from the immunological synapse [55, 56] .
We investigated here functional activity of CD44v7. Based on the observations that CD44v7 apparently has a major impact on the development of chronic colitis and that resistance of CD44v7 Ϫ/Ϫ mice toward TNBS-induced colitis was accompanied by a significantly increased number of apoptotic cells in the lamina propria, we speculated that CD44v7 interferes with the expression of pro-apoptotic genes or supports expression of anti-apoptotic genes. We tested the hypotheses by comparing responsiveness of lymphocytes deficient in or overexpressing CD44v7. We analyzed the expression level of the anti-apoptotic proteins Bcl-2, Bcl-Xl, and A1 and the phosphorylation status of the pro-apoptotic protein BAD, which exists in a phosphorylated (pBAD), inactive state and a dephosphorylated, active state [57, 58] . We also show that T cell activation is not influenced by CD44v7 expression and provide evidence that CD44v7 is excluded from the immunological synapse, possibly via its preferential association with ezrin. Instead, CD44v7 expression correlates with Bcl-2 and Bcl-Xl expression and pBAD, which supports survival of activated T cells.
MATERIALS AND METHODS

Mice
The following transgenic (TG) mice and haplotype-matched controls were used: CD44v7 Ϫ/Ϫ and CD44v7 ϩ/ϩ 129SVEV mice [25] and rCD44v4-v7 TG and non-TG (NTG) BALB/c mice. The CD44v4-v7 transgene is under the control of the Thy1 promoter, such that the gene is only expressed on some cells in the brain but on over 90% of thymocytes and over 80% of mature T cells in lymph nodes and spleen. It should be mentioned that expression of the transgene was low in Peyer's patch lymphocytes (PPL) of C57BL6 TG mice [59] . In BALB/c mice, roughly 50% of PP T cells express the transgene. Expression levels of the transgene are below those of endogenous CD44s (ϳ50%) but significantly exceed expression levels of endogenous CD44v4-v7. Mice were bred at the central animal facilities of the German Cancer Research Center (Heidelberg) and were kept under specific pathogen-free conditions. They were fed with sterilized TAP food and water ad libitum. Mice were used at the age of 8 weeks. One day before treatment with TNBS, mice were transferred from specific pathogen-free to conventional conditions. They received an intrarectal injection of 200 l TNBS (2.5% w/v) in 50% ethanol [25, 26] .
Antibodies
The following mAb were used: [60] , a subclone of which has been named ASML1.1 [59] , has been obtained after vaccination of mice with a metastasizing rat tumor line (BSp73ASML), which expresses CD44v4-v7 at an extraordinary high level. The mAb has been shown to exclusively recognize the v6 exon product [61] . Culture supernatants were purified by passage over Protein G-Sepharose, and purified mAb were used in vitro at a concentration of 10 g/ml. Anti-CD25, -CD28, -CD40, -CD69, -CD80, -CD86, -CD95, -CD95L, -CD152, and -CD154; dye-labeled [fluorescein isothiocyanate (FITC) or phycoerythrin] secondary antibody and Streptavidin; anti-ankyrin, -ezrin, and -moesin; and Phalloidin-FITC were obtained commercially (PharMingen, Hamburg, Germany). Anti-Bcl-2 (clone 124, mIgG1) and anti-pBAD (ser 112, sheep IgG) were obtained from Upstate Biotechnology (Lake Placid, NY); antiactin (polyclonal goat antiserum), anti-A1 (polyclonal goat antiserum), anti-Bcl-Xl (clone HS, mIgG1), and anti-BAD (polyclonal goat antiserum) were from Santa Cruz Biotechnology (Santa Cruz, CA).
For fluorescein-activated cell sorter (FACS) analysis, 3 ϫ 10 5 cells were stained according to routine procedures. Expression of CD152 was evaluated in permeabilized cells. The percentage of apoptotic cells was evaluated by double-staining with annexin V-FITC and propidium iodine (PI). Fluorescence was determined using a FACSstar (Becton Dickinson, Heidelberg). toneal exudate M, which served as antigen-presenting cells (APC). After 48 -72 h of culture, cells were collected for additional analyses. Where indicated, 3 H-thymidine (10 Ci/ml) was added during the last 8 h of culture. Cells were harvested, and thymidine incorporation was determined in a ␤-counter.
Cells lysis and immunoprecipitation (IP)
Cells (10 7 ) were washed twice in TNE buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM EDTA, 1 mM Na 2 VO 4 , 10 mM NaF) and were lysed in the same buffer containing 1% 3-[(3-cholamidopropyl) dimethylammonio]-1-propane sulfonate (CHAPS) for IP or 1% Nonident P-40 ϩ 0.1% sodium dodecyl sulfate (SDS) ϩ 0.25% sodium deoxycholate for Bcl-2 protein extraction. In all conditions, 1 mM phenylmethylsulfonyl fluoride (PMSF) and a protease inhibitor cocktail (Boehringer Mannheim, Germany) were added to the lysis buffer. After 30 min at 4°C, lysates were centrifuged at 13,000 g for 10 min at 4°C. Lysates were analyzed by SDS-polyacrylamide gel electrophoresis (PAGE) and Western blotting (WB) or were used for IP. For IP, lysates were precleared by the addition of 1/10 vol Protein G-Sepharose for 1 h at 4°C. Precleared lysates were incubated for 1 h at 4°C with 5 g anti-CD44 followed by an additional 1 h incubation with Protein G-Sepharose. Immune complexes were washed four times with lysis buffer. Immunoprecipitated proteins were analyzed by SDS-PAGE, followed by WB.
WB
Samples were resolved on 10% or 4 -20% gradient (for Bcl-2 proteins) SDS-PAGE under nonreducing conditions, and the proteins were transferred to Immobilon P (Millipore, Bedford, MA) at 30 V for 16 h at 4°C. Membranes were blocked [5% bovine serum albumin (BSA)], and immunoblotting was performed with the indicated antibodies, followed by the appropriate secondary horseradish peroxidase (HRP)-conjugated antibody. Blots were developed with the enhanced chemiluminescence detection system (Amersham, Little Chalfont, UK). Where indicated, antibody stripping was performed according to the manufacturer's recommendation. Densitometric analysis was performed with NIH Image 1.60 software.
Purification of glycolipid-enriched membrane (GEM) fractions and subcellular fractionation Cells (10 7 ) were seeded into antibody-coated Petri dishes and incubated for different times at 37°C. Stimulation was terminated by transferring the dishes to ice and immediate lysis of the cells for 30 min in 1 ml ice-cold TNE buffer containing 0.5% Triton X-100 and a protease inhibitor cocktail (Boehringer Mannheim). The lysate was adjusted to 40% (w/v) sucrose in TNE buffer. After transfer of the lysate to the centrifuge tube, 2 ml 30% (w/v) and 1 ml 5% (w/v) sucrose in TNE were overlaid. Samples were centrifuged for 16 -18 h at 200,000 g at 4°C. Gradient fractions (0.4 ml) were collected from the top. Fractions were analyzed by dot blot using biotinylated cholera toxin B subunit (Sigma Chemical Co., St. Louis, MO) as a GM1 marker. GEM fractions (fractions 2-4) and soluble fractions (fractions 10 -12) were pooled and analyzed on a 10% SDS-PAGE followed by WB with anti-CD44 mAb.
Statistics
Significance of differences was evaluated by the Student's t-test or by multifactorial ANOVA using Statistical Analysis Software version 8.1.
RESULTS
Activation-induced cell death in dependence on CD44v7 expression
As a model system, CD44v7-competent mice and mice with a targeted deletion of CD44v7 as well as mice expressing rCD44v4-v7 on thymocytes and T cells were used. CD44v7 is hardly detected on non-activated leukocytes, and expression on activated LNC is low as compared with CD44s. Expression levels of the CD44v4-v7 TG significantly exceed those of intrinsic CD44v7 but remain below the level of CD44s expression (Table 1 ) [27, 59] . For the evaluation of apoptosis susceptibility, LNC or PPL were stimulated in vivo by intrarectal application of TNBS (8 days), which induces a severe colitis, and/or in vitro by PHA (48 h) or high-dose (10 g/ml) anti-CD3 (48 h). Apoptosis was determined by double-staining with annexin V-FITC and PI.
LNC and PPL of CD44v7 Ϫ/Ϫ mice displayed a higher rate of apoptotic cells as compared with LNC of CD44v7 ϩ/ϩ mice if stimulated in vivo by TNBS and restimulated in vitro by anti-CD3 or PHA ( Table 2) . No differences were seen in freshly harvested LNC and PPL. The rate of apoptotic cells also did not differ between freshly harvested and in vitro-activated mLNC and PPL of untreated CD44v4-v7 TG and NTG mice. Yet, when mLNC or PPL of TNBS-treated mice were restimulated in vitro, a lower percentage of TG as compared with NTG mLNC and PPL was apoptotic. Thus, CD44v7 expression partially inhibits activation-induced apoptotic cell death of gutassociated lymphocytes. The protective effect of CD44v7 becomes most pronounced after repeated stimulation.
CD44v7 rather than its ligand interferes with activation-induced cell death
As CD44v7 is expressed on T cells as well as on APC, prevention of apoptosis could have been a result of signaling via CD44v7 or its ligand. To differentiate between these pos- 
sibilities, LNC from CD44v7
Ϫ/Ϫ and CD44v7 ϩ/ϩ mice were cultured on antigen-pulsed monocytes from CD44v7-competent and -deficient mice. Thereafter, proliferative activity and induction of apoptosis were evaluated. If apoptosis resistance would be a result of a CD44v7 ligand on T lymphocytes, CD44v7-competent and -deficient lymphocytes should be equally susceptible toward apoptosis, but susceptibility should vary depending on CD44v7 expression on the APC. CD44v7 Ϫ/Ϫ mLNC were more susceptible to apoptosis than CD44v7 ϩ/ϩ mLNC. This was irrespective of whether the cells were only stimulated in vitro or were restimulated. Expression of CD44v7 on APC did not influence the susceptibility of CD44v7 ϩ/ϩ and CD44v7 Ϫ/Ϫ mLNC to apoptosis. Overexpression of CD44v7 in mLNC of CD44v4-v7 TG mice protected cells from apoptosis, although the effect became apparent only after restimulation (Fig. 1) .
As shown in Table 3 , mLNC from CD44v7 ϩ/ϩ and CD44v7 Ϫ/Ϫ mice also proliferated equally in response to TNP-OVA presented by CD44v7-competent or -deficient APC. As APC of TG mice do not express the TG, proliferation rates could have been expected not to differ between TNP-OVApresenting APC of TG and NTG mice. However, irrespective of the APC, CD44v7
Ϫ/Ϫ mLNC responded poorly as compared with CD44v7 ϩ/ϩ mLNC. The same finding accounted for polyclonal and mitogenic stimulation. It should be noted that no differences were observed after restimulation. Also, mLNC from TG mice showed a higher proliferative response as compared with mLNC from NTG mice. As in CD44v7 Ϫ/Ϫ mLNC, the phenomenon was only observed during primary activation. A statistical evaluation of pooled data from three experiments confirmed that the proliferative activity of CD44v7
Ϫ/Ϫ , NTG, and TG mLNC did not differ significantly when TNP-OVA was presented by CD44v7-competent or -deficient APC (P value, 0.4). The primary response of CD44v7 Ϫ/Ϫ mLNC was significantly decreased (P values for TNP-OVA-pulsed APC, anti-CD3, and PHA, Ͻ0.0001), and the primary response of TG mLNC was significantly increased (P values for TNP-OVA-pulsed APC, anti-CD3, and PHA, Ͻ0.0001). The statistical analysis of repeated experiments also confirmed that secondary responses did not differ between CD44v7 Ϫ/Ϫ and CD44v7 ϩ/ϩ mLNC or between NTG and TG mLNC (P values, in the range of 0.7-0.9).
The finding that CD44v7 expression on APC does not influence proliferation or susceptibility for apoptosis supports the interpretation that expression of CD44v7 rather than of a CD44v7 ligand on T cells accounted for the resistance toward apoptosis. The fact that CD44v7-dependent differences in proliferation were only seen during primary stimulation, whereas differences in apoptosis were stimulation-independent in CD44v7 Ϫ/Ϫ mice and were visible only after repeated stimulation in mice overexpressing CD44v7 argues against the possibility that differences in the apoptosis rate may simply reflect differences in the proliferation rate. Thus, we next asked whether CD44v7 protects from apoptosis by activation of antiapoptotic or by blocking pro-apoptotic signaling molecules. CD44v7 is engaged in the activation of antiapoptotic signaling molecules CD95 expression did not differ in unstimulated or stimulated (in vivo and/or in vitro) mLNC and PPL of CD44v7 ϩ/ϩ , CD44v7 Ϫ/Ϫ , NTG, and TG mice (data not shown). However, mLNC and PPL of CD44v7 Ϫ/Ϫ mice contained a higher percentage of CD95L ϩ cells. Intensity of expression was increased at a statistically significant level in PPL only ( Fig. 2A) . The percentage of CD95L ϩ cells did not differ significantly between unstimulated lymphocytes from TG versus NTG mice. However, the percentage of CD95L-expressing cells increased during stimulation in NTG but not in TG mice (Fig. 2B) . After co-culture with TNP-OVA-pulsed APC, expression of CD95L was slightly increased in mLNC of CD44v7 Ϫ/Ϫ mice and decreased, although not at a statistically significant level, in mLNC from CD44v4-v7 TG mice. This was independent of whether the APC were CD44v7-competent or -deficient (Fig. 2C) .
As the overall percentage of CD95L ϩ cells was increased in stimulated mLNC of CD44v7 Ϫ/Ϫ as compared with CD44v7 ϩ/ϩ mice and was lower in stimulated mLNC from TG than from NTG mice, we next asked whether the influence of CD44v7 on CD95L expression may be linked to the expression level of anti-apoptotic proteins belonging to the Bcl-2 family. pBAD and the expression level of anti-apoptotic proteins Bcl-2, Bcl-Xl, and A1 were evaluated after stimulation of CD44v7-competent and -deficient LNC on pulsed APC (Fig.  3) . mLNC were lysed, and proteins were separated by gel electrophoresis and were transferred for blotting. pBAD and the expression of Bcl-2 and Bcl-Xl were strongly reduced in mLNC from CD44v7 Ϫ/Ϫ mice, irrespective of whether mLNC were co-cultured with CD44v7-competent or -deficient APC. We did not detect differences in the expression of A1. Differences in pBAD and Bcl-2 expression were less pronounced in mLNC from CD44v4-v7 TG versus NTG controls. Yet, expression of Bcl-Xl was up-regulated on mLNC of TG mice. As revealed by densitometry of three independently performed experiments (Table 4) , differences in Bcl-2, Bcl-Xl, and pBAD expression in CD44v7 ϩ/ϩ versus CD44v7 Ϫ/Ϫ mLNC and differences in Bcl-Xl expression between NTG and TG mLNC were highly significant. No differences in Bcl-2, Bcl-Xl, and pBAD expression were seen in unstimulated mLNC. Taken together, expression of CD44v7 on mLNC and PPL was accompanied by a reduction in AICD and in CD95L expression, whereas expression of Bcl-2, Bcl-Xl, and pBAD was stabilized even under stimulatory conditions, which were accompanied by a striking down-regulation of these molecules in mLNC of CD44v7-deficient mice. These features pointed toward CD44v7 being involved in maintaining rather than in inducing an immune response.
CD44v7 is involved in maintenance of the activated state
To confirm that CD44v7 is involved in regulation rather than in induction of a T cell response, expression of accessory molecules on T cells and of costimulatory molecules on APC was evaluated in mLNC after in vivo and in vitro stimulation (Fig.  4) . No differences in expression of CD44s, lymphocyte function-associated antigen-1 (LFA-1), and intercellular adhesion molecule-1 (ICAM-1) were seen in lymphocytes from TG versus NTG and CD44v7 Ϫ/Ϫ versus CD44v7 ϩ/ϩ mice (data not shown). Deletion of the CD44v7 exon product was accompanied by a more pronounced up-regulation of CD69 and CD25 on mLNC after in vitro stimulation or restimulation as compared with CD44v7 ϩ/ϩ lymphocytes. A higher percentage of unstimulated mLNC from CD44v4-v7 TG as compared with ϩ/ϩ and CD44v7 Ϫ/Ϫ 129SVEV mice (A) and from CD44v4-v7 TG and NTG mice (B) were freshly harvested from untreated mice or from mice 8 days after intrarectal TNBS treatment. Where indicated, mLNC were stimulated in vitro with PHA or with anti-CD3 (10 g/ml) for 48 h or with antigen-pulsed APC (C) as described in Figure 1 . Thereafter, expression of CD95L was evaluated by flow cytometry. Mean values of three independently performed experiments of the percentage of CD95L expressing mLNC and PPL (A-C) and of the mean intensity of CD95L expression (A and B) are presented. *, Significant differences (P Ͻ 0.01) in the percentage of CD95L ϩ lymphocytes of CD44v7 ϩ/ϩ versus CD44v7 Ϫ/Ϫ and CD44v4-v7 TG versus NTG mice; ࡗ, significant differences (P Ͻ 0.01) in the mean intensity of expression (छ, differences are not significant).
NTG mice expressed CD69 and CD25. However, in TG mice, the percentage of CD69 ϩ and CD25 ϩ mLNC hardly increased after stimulation (Fig. 4A) .
It has been shown that CD44/CD44v7 becomes up-regulated by the CD40 -CD40L interaction [25, 62] . It is also known that CD40 -CD40L interaction can interfere with the activation of the apoptotic cascade [63] . Hence, expression of CD40/CD40L was of particular interest with respect to the anti-apoptotic features of CD44v7. Expression of CD40 was unaltered in CD44v7 Ϫ/Ϫ as compared with CD44v7 ϩ/ϩ lymphocytes but was up-regulated in CD44v4-v7 TG as compared with NTG lymphocytes. However, expression of CD40L was reduced in unstimulated and stimulated CD44v7 Ϫ/Ϫ lymphocytes. CD44v4-v7 TG lymphocytes expressed CD40L at a slightly but not statistically, significantly increased percentage (Fig. 4B) .
CD40 expression is also involved in the up-regulation of CD80 and CD86, which can influence CD28 and CD152 (CTLA-4) expression. CD80 and CD86 expression did not differ between CD44v7 ϩ/ϩ and CD44v7 Ϫ/Ϫ or between NTG and TG mice. Furthermore, no significant differences were seen in CD28 expression. This accounted for freshly harvested mLNC as well as for cells harvested after TNBS treatment (data not shown). Expression of CD152 was slightly increased in mLNC from CD44v7 Ϫ/Ϫ as compared with CD44v7 ϩ/ϩ mice and was slightly reduced in mLNC of TG as compared with NTG mice (Fig. 4C ). An analysis of costimulatory and accessory molecules on PPL of CD44v7-competent, CD44v7-deficient, and CD44v4-v7-TG mice revealed similar features as described for mLNC (data not shown).
These features provided mainly two insights. Except for the influence of constitutively expressed CD44v7 (TG) on CD40 expression, CD44v7 did not influence expression of costimulatory molecules on APC. Yet, CD44v7 (over)expression was accompanied by reduced up-regulation of the activation markers CD25 and CD69 and a distinct reduction in CD152 ϩ T cells, which comprise regulatory T cells. These features are compatible with CD44v7, acting during regulation rather than during induction of response.
Fig. 3. Regulation of Bcl-2 family proteins and CD44v7 expression. (A) Freshly harvested mLNC from CD44v7
ϩ/ϩ and CD44v7 Ϫ/Ϫ 129SVEV mice as well as from CD44v4-v7 TG and NTG BALB/c mice and (B) mLNC co-cultured with antigen-pulsed APC as described in Figure 1 were lysed and after electrophoresis, blotted with anti-Bcl-Xl, anti-Bcl-2, anti-pBAD, anti-BAD, and anti-A1. Blotting with anti-actin is included as control. a Mean values of three independently performed WB; the actin signal has arbitrarily been defined as 1. b APC were derived from CD44v7-competent mice.
Fig. 4. Expression of accessory molecules and their ligands on mLNC in relation to CD44v7 expression. mLNC from CD44v7
Ϫ/Ϫ , CD44v7 ϩ/ϩ , CD44v4-v7 TG, and NTG mice were stimulated in vivo by TNBS and/or in vitro by anti-CD3. Expression of the activation markers CD69 and CD25 (A), CD40 and CD40L (B), and CD152 (C) was evaluated by flow cytometry. Expression of these markers on freshly harvested mLNC of untreated mice is shown for comparison. The experiment was repeated three times and revealed comparable results. *, Significant differences (P Ͻ 0.01) between mLNC of CD44v7 ϩ/ϩ versus CD44v7 Ϫ/Ϫ and CD44v4-v7 TG versus NTG mice.
CD44v7 and CD44s are recovered from different membrane microdomains and associate with different cytoskeletal-linker proteins
We and others [39, 43, 64] demonstrated that CD44s is constitutively associated with lck and that upon cross-linking CD44s together with the CD3 complex, CD44s is driven into the immunological synapse, where it supports T cell activation or apoptosis depending on the maturation state of the T cell [39] . The opposing features described for CD44v7 could be a result of CD44s and CD44v7 being located in different membrane microdomains and associating with distinct linker proteins. To test this hypothesis, we first looked for the presence of CD44s and CD44v7 in light (Triton X-100-insoluble) and dense (Triton X-100-soluble) membrane fractions, which were separated by sucrose gradient centrifugation. mLNC were stimulated in vitro by cross-linking CD3 or CD44 or in vivo by TNBS treatment. CD44v7 Ϫ/Ϫ and CD44v7 ϩ/ϩ mLNC ( Fig. 5A and Table 5 ) and CD44v4-v7 TG and NTG mLNC (Fig. 5B and Table 5 ) were lysed, and the lysates were separated by sucrose density-gradient centrifugation. Proteins in light and dense fractions of the sucrose gradient were separated by gel electrophoresis and were blot-
Fig. 5. CD44v7 is excluded from the immunological synapse. Unstimulated and in vivo (TNBS)-stimulated mLNC from CD44v7
ϩ/ϩ versus CD44v7 Ϫ/Ϫ 129SVEV mice (A) and unstimulated mLNC from CD44v4-v7 TG and NTG BALB/c mice (B) were cross-linked with anti-CD3, anti-CD44, or anti-rat CD44v6 (only mLNC of TG mice). LNC were lysed and subjected to sucrose gradient centrifugation. Light (Triton X-100-insoluble) and dense (Triton X-100-soluble) fractions were collected and pooled, and proteins were separated by gel electrophoresis and blotted with anti-mouse CD44 (IM-7) and/or anti-rat CD44v6 (A2.6). Ϫ/Ϫ mice. After in vitro restimulation with anti-CD3 of mLNC of TNBS-treated mice, enrichment of CD44 in the light (raft) fraction was mostly seen with mLNC of CD44v7-deficient mice. Furthermore, as opposed to mLNC from NTG mice, CD44 was not enriched in the light fraction of TG mLNC after cross-linking CD3 or CD44. Cross-linking CD44v4-v7 via anti-rat CD44v6 did not support translocation of CD44 or of the CD44v4-v7 TG into the light raft fraction. The statistical evaluation of densitometric data from three independently performed experiments revealed that in the absence of any stimulation and after in vivo TNBS treatment, significantly more CD44 was recovered in the light fraction of CD44v7 Ϫ/Ϫ than of CD44v7 ϩ/ϩ mice. By anti-CD3 or IM-7 cross-linking, significantly less CD44 was recruited into the light fraction of TG mLNC than of NTG mLNC. Also, significantly less CD44v4-v7 than CD44 was recovered from the light fraction of TG mLNC (Table 5 ).
These findings indicate that CD44v7-containing isoforms, as opposed to the CD44s isoform, are not recruited toward the immunological synapse upon T cell stimulation. Therefore, it was tempting to speculate that CD44s and CD44v7 may be associated with different cytoskeletal-linker proteins. It has been described that CD44 can associate with ankyrin [47] but also with members of the ERM family [48] . The latter have been shown to be important for the translocation of CD43 out of the immunological synapse upon T cell stimulation (reviewed in ref. [65] ). To see whether the differences in the recruitment of CD44s versus CD44v7 toward the immunological synapse may be based on a different association with ezrin and moesin, mLNC from CD44v7-deficient and from CD44v4-v7-TG mice were stimulated for 12 h by cross-linking CD3 or CD44. Cells were lysed, and lysates were precipitated with IM-7 and A2.6, respectively. After electrophoresis, WB was performed with anti-moesin and anti-ezrin ( Fig. 6 and Table  6 ). IM-7 immunoprecipitates of unstimulated mLNC from CD44v7-competent and -deficient mice contained comparable amounts of ezrin. After cross-linking CD44, significantly less ezrin became CD44-associated in CD44v7 Ϫ/Ϫ than in CD44v7 ϩ/ϩ mLNC. Also, significantly less moesin was associated with CD44 in CD44v7 Ϫ/Ϫ mLNC than in CD44v7 ϩ/ϩ Fig. 6 . Co-localization of CD44v7 with moesin and ezrin. (A) mLNC from CD44v7 Ϫ/Ϫ and CD44v7 ϩ/ϩ and (B) CD44v4-v7 TG and NTG mice were stimulated in vitro by anti-CD3, anti-CD44, or anti-CD44v6 (only TG mLNC) cross-linking. Cells were lysed and immunoprecipitated with anti-mouse CD44 (IM-7) and/or anti-rat CD44v6 (A2.6). Precipitated proteins were separated by gel electrophoresis and were blotted with anti-ezrin, anti-moesin, anti-CD44, or anit-CD44v6 and the respective HRP-labeled secondary antibodies. mLNC. This was seen with unstimulated and stimulated mLNC. BALB/c mLNC of TG and NTG mice contained too little moesin for a comparative evaluation. However, in mLNC of TG mice, a significantly lower amount of ezrin was precipitated by IM-7 than by A2.6. This also becomes apparent by the statistical evaluation of the relative signal intensity in three independently performed blots (Table 6 ). Thus, ezrin and moesin (data only available for CD44v7 Ϫ/Ϫ and control mice) can associate with CD44s and CD44v7, but the ERM proteins associate preferentially with CD44v isoforms. The exclusion of CD44v7 from lipid rafts may well be a result of its preferential association with ERM proteins.
Taken together, CD44v7 supports maintenance of an activated state, which is accompanied by low-level CD152 expression and a persistently high level of anti-apoptotic proteins. Our findings suggest that this is a result of the failure of CD44v7 recruitment into the immunological synapse by its preferential association with ezrin.
DISCUSSION
The mucosa-associated immune system is permanently exposed to intraluminal, mostly nonpathogenic antigens, and it is supposed that the gut-associated immune system disposes of particular regulatory mechanisms to avoid continuous activation of gut-associated lymphocytes [66] . Accordingly, chronic IBDs are supposed to be, besides other factors, a result of a failure of regulatory elements of the immune system [67] . We recently described that mice with a targeted deletion of CD44v7 resist induction of a TNBS-induced colitis [25] and that a TNBS-induced colitis can be cured by a CD44v7-specific antibody. It should be mentioned that neither the CD44v7-specific antibody nor targeted deletion of CD44v7 had any impact on the acute, ethanol-mediated inflammation, which is seen during the first 3 days after TNBS application [26] . Here, we demonstrate that CD44v7 apparently does not participate in lymphocyte activation but supports pBAD and sustained expression of Bcl-2 and Bcl-Xl in repeatedly stimulated lymphocytes. This was deduced from in vivo and in vitro analysis of mLNC from CD44v7-deficient and constitutively CD44v4-v7-overexpressing mice. As a result of instability of the hybridoma secreting a murine CD44v7-specific mAb, findings could not be controlled by an additional antibody blockade.
IBD is a TH-1-mediated autoimmune disease [3, 4, 14, 15] , and we have shown before that anti-CD44v7 treatment supports the secretion of IL-10, which leads to down-regulation of IFN-␥ secretion [26] . These features were a result of a direct activation of APC by cross-linking via the CD44v7-specific antibody [26] . However, such a functional principle does not provide an explanation for the resistance of CD44v7 Ϫ/Ϫ mice toward induction of colitis [25] . Furthermore, there is evidence that IL-12 is pivotal only at the starting period of IBD [16] . The fact that CD44v7
Ϫ/Ϫ /IL-10 Ϫ/Ϫ mice do not develop chronic colitis [25] also argues against an overshooting TH-1 reaction as the exclusive principle of persisting inflammation. Hence, additional activities of CD44v7 should be important for maintenance of the inflammatory state. It is known that LPL are rather resistant toward apoptosis [23, 68] , and significantly more apoptotic cells are seen in the inflamed gut of CD44v7 Ϫ/Ϫ as compared with CD44v7 ϩ/ϩ mice, which could be confirmed by annexin V and PI staining of in vitro, restimulated mLNC from TNBS-treated CD44v7 Ϫ/Ϫ and CD44v4-v7 TG mice. The finding pointed toward CD44v7, blocking activation of the apoptotic cascade or sustaining high-level expression of anti-apoptotic molecules.
To differentiate between these possibilities, expression of pro-and anti-apoptotic molecules was evaluated. CD95 expression was unaltered, and CD95L expression was not significantly reduced in lymphocytes of CD44v7-competent as compared with CD44v7-deficient mice. Yet, Bcl-Xl expression was clearly elevated in lymphocytes of CD44v4-v7 TG mice and was further increased after repeated stimulation (data not shown), whereas in control mice, Bcl-Xl and pBAD but not BAD expression was lowered. Bcl-2, Bcl-Xl, and pBAD were hardly detectable in stimulated LNC of CD44v7 Ϫ/Ϫ mice. Differences in expression of anti-apoptotic molecules were most pronounced after antigenic stimulation, i.e., were less striking after stimulation by PHA or cross-linking CD3 (data not shown). The features argue against a dominating influence of CD44v7 on the CD95/CD95L pathway. Instead, CD44v7 obviously supports expression of anti-apoptotic molecules.
The analysis of lymphocyte activation markers corroborated that CD44v7 may well be important for prevention of AICD but is unlikely to play a major role in lymphocyte activation. Neither the constitutive overexpression nor the absence of CD44v7 had any bearing on lymphocyte activation markers such as LFA-1, CD44s, and CD28 and did not trigger CD80 and CD86 expression. Yet, expression of some costimulatory and accessory molecules apparently was not fully independent of CD44v7 expression. First, CD69 and CD25 expression was elevated in unstimulated mLNC of CD44v4-v7 TG mice but hardly increased during activation. The feature could well be connected to the accelerated response of LNC of CD44v4-v7 TG mice toward a nominal antigen [59] but is not of relevance in chronic inflammation (R. M., unpublished). Second, CD40 and CD40L expression was elevated in mLNC of CD44v4-v7 TG mice, whereas CD40L expression was low in lymphocytes of CD44v7 Ϫ/Ϫ mice. High CD40/CD40L expression levels have also been described in patients with IBD [18] . A CD40/ CD40L interaction is supposed to trigger early up-regulation of a not yet defined CD44 isoform, which in turn influences CD40/CD40L expression [62] . The CD44 isoform may well be CD44v7, which is rapidly up-regulated by CD40L cross-linking [25] . Third, expression of CTLA-4 was low in TG mice but high in CD44v7 Ϫ/Ϫ mice, and triple-fluorescence staining for CD4, CD25, and cytoplasmic CTLA-4 revealed a higher percentage of CD4 ϩ CD25 ϩ CTLA-4 ϩ mLNC in CD44v7 Ϫ/Ϫ as compared with CD44v7 ϩ/ϩ mice (M. Z., unpublished finding). It has recently been described that CD4 ϩ CD25 ϩ CTLA ϩ regulatory T cells are important in the control of IBD [20, 21] .
Taken together, expression of CD44v7 appears to be linked to CD40L expression and possibly has a negative impact on regulatory T cells. More essential, the analysis of activation markers provided no evidence for an involvement of CD44v7 in lymphocyte activation.
The minor impact on CD95L expression and the failure to support expression of activation markers such as CD25 and CD69 expression are in clear distinction to CD44s, which functions as an accessory molecule in T cell activation and AICD. Cross-linking CD44s supports phosphorylation of lck, fyn, and additional kinases [39] , known to become activated during the initiation of a T cell response [69, 70] . Importantly, the accessory function of CD44s depends on its recruitment in the lipid-rich microdomain of the immunological synapse [43] . Thus, we speculated that the failure to support T cell activation and the stabilization of anti-apoptotic gene expression may be a result of CD44v7 locating in different membrane compartments and associating with different adaptor molecules.
It has been described that upon TCR engagement, membrane molecules become resorted [41, 42, 54 -56, 71, 72] . Although the TCR/CD3 complex, CD4/CD8, and additional accessory molecules are recovered from the central immunological synapse, other molecules such as integrins form an inner rim, and e.g., CD43 being excluded from the synapse is recovered in an outer rim [73, 74] . Sorting can be guided by the cytoskeletal-linker proteins ezrin and moesin [54 -56] . Therefore, it became of interest whether CD44v7, too, may become excluded from the synapse by associating with ezrin and/or moesin. Ezrin and moesin were present in IM-7 precipitates of CD44v7-competent and -deficient mice. Yet, a densitometric analysis revealed that only a minor portion of CD44s was associated with ezrin, a fivefold higher amount of ezrin coprecipitated with CD44v4-v7, and more moesin coprecipitated with CD44 in CD44v7 ϩ/ϩ compared with CD44v7 Ϫ/Ϫ cells. It is interesting that although CD44 was the first transmembrane protein reported to associate with the ERM family [48] , it was also described that only a minor part of CD44 associates with ERM proteins during lymphocyte activation [54] . There are at least two possible explanations for the preferential association of ERM proteins with CD44v. First, CD44s, which is rapidly recruited into the immunological synapse, supports the phosphorylation of ERM proteins as a result of its constitutive association with lck and fyn. The activated ERM proteins migrate out of the synapse and reassociate with membrane proteins as well as polymerized actin [75, 76] . As CD44 variant isoform expression becomes up-regulated only during the process of lymphocyte activation, the newly appearing CD44v molecules may more likely associate with the active form of ezrin/moesin than CD44s, which is already engaged in the TCR/CD3 signaling complex in the inner synapse. The strong association of ezrin with constitutively expressed CD44v4-v7 in TG mice strengthens this hypothesis. Second, CD44v isoforms are associated with additional transmembrane proteins, which are excluded from the immunological synapse. A CD44 variant isoform-selective association with other membrane molecules could be demonstrated for CD44v-expressing tumor cells [77] . It remains to be explored whether this also accounts for CD44v7 expressed on lymphocytes. Irrespective of the mechanism underlying the preferential association of CD44v with ERM proteins, this association exludes CD44v7 from the immunological synapse and thus provides a convincing explanation for CD44v7 not functioning as an accessory molecule in T cell activation. Could the association with ezrin also support prevention of apoptosis? Activated ERM proteins are known to associate with signaltransducing molecules such as regulators of Rho-family GTPases and phosphatidylinositol-3 kinase (PI-3K) [78 -80] . Upon association, the latter translocates to the membrane and phosphorylates phosphatidylinositol-4,5-bisphosphate, which leads to activation of AKT [81] , which is known to transduce antiapoptotic signals [57, 58, 80, 81] . It was recently described that ICAM-2 induces tyrosine phosphorylation of ezrin and PI-3K translocation, AKT activation, and phosphorylation of AKT targets, thus preventing B cell death [82] . Our findings suggest that CD44v7 may support T cell survival via a similar signaling pathway.
We briefly want to discuss whether the presented data are in line with our hypothesis that CD44v7 sustains chronic IBDs by preventing down-regulation of anti-apoptotic genes and as a consequence, AICD, and whether this can be a physiologically relevant mechanism. With respect to the potential, physiological function of CD44v7, it is important to remember that CD44v7 expression on T cells is mainly induced via CD40L engagement [25] or by (repeated) antigenic stimulation but hardly by mitogens or by cross-linking the TCR/CD3 complex. Inflammatory reactions start with the recruitment of elements of nonadaptive-immune defense, followed by the infiltration of CD4 ϩ cells, the first wave of infiltrating T cells mostly being nonantigen-specific. As outlined above, CD44v7 expression on T cells is apparently restricted to TH cells, which become activated by directly contacting APC. Taking this expression profile, it becomes unlikely that CD44v7 functions during the early period of an inflammatory reaction. It is known that the gut-associated immune system disposes on a high level of regulatory elements to avoid persisting activation of lymphocytes [19 -22] . We would like to propose that the gut also uses a fail-safe mechanism in the sense that apoptosis protects a minority of antigen-specific TH cells. The expression profile of CD44v7 would be compatible with CD44v7 contributing to the protection of activated TH cells.
Such a physiological function of CD44v7 would also be in line with our observations regarding the impact of CD44v7 on TNBS-induced colitis, i.e., that mice with a targeted deletion of the CD44v7 exon product are resistant toward experimental colitis and that application of a CD44v7-specific antibody prevents the development of chronic colitis. CD44v7 Ϫ/Ϫ mice as well as anti-CD44v7-treated mice develop an unimpaired, initial inflammatory reaction [25, 26] . Furthermore, the inflammatory reaction observed during the initial 3 days after TNBS application is not aggravated in CD44v4-v7 TG mice (data not shown). The observations support our finding that CD44v7 does not contribute to T cell activation. As CD44v4-v7 TG mice express CD44v4-v7 constitutively, it also becomes unlikely that the failure to detect an impact of CD44v7/anti-CD44v7 on early inflammatory events is a result of the fact that CD44v7 expression is low in unstimulated lymphocytes. At ϳ5 days after TNBS application, when an anti-CD44v7 treatment or a CD44v7 deficiency becomes effective, a reasonable number of clonally expanded, antigen-specific TH cells will have infiltrated the gut. Finally, it has already been demonstrated that a blockade of CD44v7 [26] is therapeutically very effective. According to the presented data and our proposed hypothesis, anti-CD44v7 should neither affect primary responsiveness nor be accompanied by an overshooting down-regulation of response.
Taken together, we could demonstrate that CD44v7 is important in preventing AICD by stabilizing expression of antiapoptotic molecules. CD44v7 preferentially associates with ERM proteins, which exclude the molecule from the immunological synapse. The signaling cascade initiated by the CD44v7-ERM complex, which results in pBAD and the sustained expression of BcL-Xl and Bcl-2, remains to be explored.
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